Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
North Carolina Medical Journal|July 22, 2014
The ethics of clinical trials for cancer therapyLynn J Howie, Jeffrey M PeppercornJournal of Surgical Oncology|January 16, 2016
Neoadjuvant use of ipilimumab in locally advanced melanomaLynn J Howie, Douglas S Tyler, April K S SalamaJournal of the National Cancer Institute|December 19, 2018
Blinding and Patient-Reported Outcome Completion Rates in US Food and Drug Administration Cancer Trial Submissions, 2007-2017Jessica K Roydhouse, Bellinda L King-Kallimanis, Lynn J Howie, et al.Journal of Pain and Symptom Management|April 3, 2012
To stent or not to stent: an evidence-based approach to palliative procedures at the end of lifeSydney M Dy, Stephanie M Harman, Ursula K Braun, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 27, 2014
There is a mismatch between the medicare benefit package and the preferences of patients with cancer and their caregiversDonald H Taylor, Marion Danis, S Yousuf Zafar, et al.Clinical Trials (London, England)|March 19, 2019
Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directionsBellinda L King-Kallimanis, Lynn J Howie, Jessica K Roydhouse, et al.JAMA Oncology|March 2, 2018
A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A ReviewJulia A Beaver, Lynn J Howie, Lorraine Pelosof, et al.Clinical Breast Cancer|April 5, 2018
Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive PhenotypeJeremy Force, Lynn J Howie, Sara E Abbott, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2018
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn J Howie, Nancy S Scher, Laleh Amiri-Kordestani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 28, 2019
Outcomes of Older Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled AnalysisLynn J Howie, Harpreet Singh, Erik Bloomquist, et al.Pageof 2